ACAD
Acadia Pharmaceuticals Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$25.41
+0.57 ▲ +2.27%
🌙 7월 27일 6:06 PM ET (한국 7/28 07:06)
$25.35
-0.04 ▼ -0.16%
아카디아 파마슈티컬즈(ACAD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$4.4B
스몰캡
P/E
11.6
저평가 구간
배당수익률
없음
52주 위치
66%
저점 +29% · 고점 -10%
애널리스트
매수
B-
Fundamental health
vs. Biotechnology 중형주
수익성 Top 9%
성장 Top 51%
밸류에이션 Top 59%
재무 안정 Top 49%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 2년 (not other companies).
Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 11원. Over the past 2년, it usually traded around 15원. On the cheaper side versus its own history.
Pricy doesn't mean bad — it means expectations are already baked in.· based on 2.1 profitable years
| Index | RUT | P/E | 11.57 | EPS (ttm) | 2.2 | Insider Own | 1.28% | Shs Outstand | 171.1M | Perf Week | 1.26% |
| Market Cap | 4.35B | Forward P/E | 30.48 | EPS next Y | 115.02% | Insider Trans | -2.69% | Shs Float | 169.1M | Perf Month | 7.1% |
| Enterprise Value | 3.55B | PEG | - | EPS next Q | 0.06 | Inst Own | 96.73% | Short Float | 6.52% | Perf Quarter | 15.69% |
| Income | 0.38B | P/S | 3.97 | EPS this Y | -83.15% | Inst Trans | -0.8% | Short Ratio | 6.86 | Perf Half Y | -5.35% |
| Sales | 1.10B | P/B | 3.48 | EPS next 5Y | -13.34% | ROA | 27.44% | Short Interest | 11.03M | Perf YTD | -4.89% |
| Book/sh | 7.29 | P/C | 5.11 | EPS past 3/5Y | - | ROE | 37.32% | 52W High | -10.39% ($28.35) | Perf Year | 9.27% |
| Cash/sh | 4.97 | P/FCF | 38.3 | Sales past 3/5Y | 27.48% 19.39% | ROIC | 29.19% | 52W Low | 29.02% ($19.69) | Perf 3Y | -12.46% |
| Dividend Est. | - | EV/EBITDA | 38.29 | EPS Y/Y TTM | 61.4% | Gross Margin | 91.47% | Volatility(W/M) | 2.94% 3.39% | Perf 5Y | 20.12% |
| Dividend TTM | - | EV/Sales | 3.24 | Sales Y/Y TTM | 9.93% | Oper. Margin | 7.39% | ATR (14) | 0.81 | Perf 10Y | -32.14% |
| Dividend Ex-Date | - | Quick Ratio | 3.48 | EPS Q/Q | -81.36% | Profit Margin | 34.3% | RSI (14) | 58.03 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | 9.72% | SMA20 | -0.56% ($25.55) | Beta | 0.82 | Target Price | $32.8 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/4 | SMA50 | 9.35% ($23.24) | Rel Volume | 0.87 | Prev Close | $24.84 |
| Employees | 798 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -60.4% -4.34% | SMA200 | 8.01% ($23.53) | Avg Volume(3M) | 1.61M | Price | $25.41 |
| IPO | 2004/5/27 | Option/Short | Yes/Yes | Trades | 15323 | Volume | 1,399,399 | Change | 2.27% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $268M (YoY +10%) · 순이익 $4M (YoY -81%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red
Acadia Pharmaceuticals Inc (ACAD) Investment Analysis
What kind of company is Acadia Pharmaceuticals Inc?
아카디아 파마슈티컬즈(ACAD) 방어주
Healthcare · Biotechnology
#1510 by Market Cap — Mid-Cap
🧠 A commercial-stage biopharmaceutical company that sells treatments for central nervous system and rare diseases. It commercializes and sells therapies indicated for Parkinson's disease psychosis and Rett syndrome, among others, while pursuing stable, profit-based earnings and pipeline expansion. A biopharmaceutical company specializing in central nervous system and rare diseases.
Learn more about Acadia Pharmaceuticals Inc →Market Cap
$4.4B
Approx. KRW 6.0 trillion
⚖️ 2% of Samsung Electronics
Market Cap Rank1510
Employees798people
IPO2004/05/27
Current Price$25.41 ≈ 34,812원
Key Events
⏰ Upcoming events
🔔 Earnings release D-8
8월 4일 (화) · 장 마감 후
예상 EPS $0.06
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS -60.4% 매출 -4.3%
🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후 EPS +1067.9% 매출 -3.0%
Is it profitable?
Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
7.4%
✓ 우수
Net Margin
Share of revenue left after taxes and interest are paid
34.3%
✓ 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
91.5%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
37.3%
✓ 우수
ROA
Annual earnings relative to total company assets
27.4%
✓ 우수
ROIC
Return generated per dollar invested in the business
29.2%
✓ 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.04
✓ Healthy debt
Current Ratio
Liquid assets available to cover liabilities due within a year
3.59
✓ 양호
Quick Ratio
Liquid assets excluding inventory, available for immediate use
3.48
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$32.80
현재가 대비 +29.1%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
30.48배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
+115.0%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
-13.3%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-39.7%
평균 서프라이즈
2026.05.06
하회
실적 $0.02 · 예상 $0.08 -75.2%
2026.02.25
하회
실적 $0.14 · 예상 $0.14 -4.2%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Growth Expected to Slow
Historical growth is expected to lose momentum
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-83.2%
매우 부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+115.0%
우수
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
-13.3%
매우 부진
📊 How much has it grown? (actual results)
Past 5-Year Revenue
How much revenue grew over the past 5 years
+19.4%
우수
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+9.7%
양호
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -48%p below the market
ACAD +20.1% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-48.2%p
Significantly behind the market
vs Health Care (XLV)
-4.4%p
roughly in line with the sector average
1-year basis
vs S&P 500
-6.7%p
slightly behind the market
vs Health Care (XLV)
-10.4%p
behind the sector average
Rank among peers
5-year return Lower-Mid (lower 39%) Based on 64 peers
1-year return Bottom 19% Based on 76 peers
Current position within 52-week range
Low (-29.0%p) High (-10.4%p)
Current price is 29.0% above the 52-week low and 10.4% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-17.8%
Annualized volatility
37.2%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $25.41 below the midline ($25.55). Normal downward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Neutral zone — weak trend
MACD 0.493 · Signal 0.712 · Hist -0.218. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bullish zone
RSI 58.1 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 51.8.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
In line with the industry average
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales, In line with peers on Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Assets Cheap
Vs. Sales Cheap
Vs. Cash Flow Mid-range
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
11.57x
✓ Cheap
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
30.48x
✓ Fair
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.48x
✓ Very cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.97x
✓ Very cheap
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
38.29x
✓ Fair
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
38.30x
✓ Fair
Analyst target price (reference)
$32.80 vs. current price +29.1%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology
Who owns it?
Ownership backdrop is unfavorable
Insider modest net selling -2.7% · Institutional modest net selling -0.8% · Short interest moderate 6.5% · Short interest up +0.9pp over last 90d
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-2.7%
Insiders net selling
🏦 Institutions (funds & investors)
-0.8%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 96.7%
Institution-led, stable structure
🧑💼 Insiders 1.3%
Typical level
👤 Retail investors (estimated) 2.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
6.5%
Moderate
Past 90 days 📈 +0.9%p increase
Short interest days to cover
6.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 171.1M주
Float (tradable shares) 169.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding ACAD
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| ACAD This Stock | $4.4B | 11.6 ▲ | 3.5 ▼ | 37.32% ▲ | - | +2.3% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 아카디아 파마슈티컬즈(ACAD)?
아카디아 파마슈티컬즈(ACAD) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACAD?
The market cap of ACAD is approximately $4.4B, ranking 1,510 within its sector.
What is the P/E ratio of ACAD?
ACAD has a P/E ratio of approximately 11.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ACAD?
ACAD has recorded a 52-week high of $28.35 and a low of $19.69.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.